Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study

Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study

Abstract Background and aims Direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment. However, difficult‐to‐cure/cirrhotic patients typically require a longer treatment duration...

Full description

Bibliographic Details
Main Authors: Eric Lawitz, Fred Poordad, Julio A. Gutierrez, Maria Beumont, Greet Beets, Ann Vandevoorde, Pieter Van Remoortere, Donghan Luo, Leen Vijgen, Veerle Van Eygen, Mohamed Gamil
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:Health Science Reports
Subjects:
decompensation
hepatitis C
portal hypertension
simeprevir
sofosbuvir
Online Access:https://doi.org/10.1002/hsr2.145

Internet

https://doi.org/10.1002/hsr2.145

Similar Items